Status message

Active context: kki_bg_colors_yellow

A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder

Principal Investigator:

The objective of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with MDD.

In addition, the study is designed to obtain pharmacokinetic (PK) data to define the PK profile of vilazodone in the pediatric population (7–17 years of age).

Study VLZ-MD-22 will be a multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group, flexible-dose study in pediatric patients, 7 to 17 years of age. The study will include a total of 9 visits and will be approximately 10 weeks in duration.

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.